V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Nektar Therapeutics Executive Compensation (FY25)

NKTR · Executive and director compensation, fiscal 2023 to 2025

The paid brief on Nektar Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Nektar Therapeutics brief$1,500Get the executive brief
198 figures on this page: 187 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Howard Robin
Latest say-on-pay support
=
June 4, 2026
This company is not required to report a chief executive pay ratio.

More on Nektar Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Howard Robin: $3,762,693 → $6,256,954 (66.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Nektar Therapeutics' chief executive and what were they paid?
Howard Robin, President and Chief Executive Officer, received $6,256,954 in total compensation for fiscal 2025. Robin's total moved 66.3% higher from the $3,762,693 reported for fiscal 2024.
What was Nektar Therapeutics' say-on-pay result?
The say-on-pay proposal drew 99.1% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Nektar Therapeutics' peer group?
Companies named in the disclosed peer group include Amylyx Pharmaceuticals, Arcus Biosciences, Astria Therapeutics, Celldex Therapeutics and Compass Therapeutics, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard Robin
President and Chief Executive Officer
◇——◇◇—◇◇
Jonathan Zalevsky
Chief Research and Development Officer
◇——◇◇—◇◇
Mark Wilson
Former Chief Legal Officer
◇——◇◇—◇◇
Sandra Gardiner
Interim Chief Financial Officer
Served on an interim basis
——————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard Robin
President and Chief Executive Officer
◇——◇◇—◇◇
Jonathan Zalevsky
Chief Research and Development Officer
◇——◇◇—◇◇
Mark Wilson
Former Chief Legal Officer
◇——◇◇—◇◇
Sandra Gardiner
Interim Chief Financial Officer
Served on an interim basis
——————◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Howard Robin
President and Chief Executive Officer
◇—◇◇◇—◇◇
Jonathan Zalevsky
Chief Research and Development Officer
◇—◇◇◇—◇◇
Sandra Gardiner
Interim Chief Financial Officer
Served on an interim basis
——————◇◇
Mark Wilson
Former Chief Legal Officer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Howard W. RobinRSU◇——◇——◇
Howard W. RobinOPTION◇——◇—◇◇
Jonathan ZalevskyOPTION◇——◇—◇◇
Jonathan ZalevskyRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jonathan ZalevskyOption◇—◇12/17/2028
Option◇—◇12/21/2033
Option◇—◇08/14/2030
Option◇—◇12/11/2027
Option◇—◇12/11/2027
Option◇—◇12/12/2032
Option◇—◇9/30/2027
Option◇—◇12/12/2032
Option◇—◇12/12/2031
RSU◇◇——
PSU◇◇——
Option◇—◇12/15/2029
PSU◇◇——
Mark WilsonOption◇—◇3/31/2026
Option◇—◇3/31/2026
Option◇—◇3/31/2026
Option◇—◇3/31/2026
Option◇—◇3/31/2026
Option◇—◇3/31/2026
Option◇—◇3/31/2026
Howard RobinOption◇—◇12/15/2029
Option◇—◇12/17/2028
Option◇—◇12/11/2027
Option◇—◇12/12/2032
Option◇—◇12/12/2031
PSU◇◇——
Option◇—◇12/21/2033
Option◇—◇12/11/2027
RSU◇◇——
PSU◇◇——
Option◇—◇08/14/2030
Option◇—◇12/12/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert B. Chess
Board chair
◇—◇———◇
Roy A. Whitfield
Lead independent director
◇—◇———◇
R. Scott Greer
◇—◇———◇
Diana Brainard, M.D
◇—◇———◇
Jeff Ajer
◇—◇———◇
Howard W. Robin served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Amylyx Pharmaceuticals AMLX
  • Arcus Biosciences RCUS
  • Astria Therapeutics ATXS
  • Celldex Therapeutics CLDX
  • Compass Therapeutics CMPX
  • Corvus Pharmaceuticals CRVS
  • Dianthus Therapeutics DNTH
  • IDEAYA Biosciences IDYA
  • Intellia Therapeutics NTLA
  • Kodiak Sciences KOD
  • Olema Pharmaceuticals OLMA
  • Praxis Precision Medicines PRAX
  • Relay Therapeutics RLAY
  • Rezolute RZLT
  • Vera Therapeutics VERA
  • Viridian Therapeutics VRDN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024May 23, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021June 8, 2022=◇◇◇
2020June 10, 2021=◇◇◇
2019June 17, 2020=◇◇◇
2018June 14, 2019=◇◇◇
2017June 26, 2018=◇◇◇
2016June 14, 2017=◇◇◇
2015June 23, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Nektar Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Nektar Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Nektar Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Nektar Therapeutics' disclosed peer group is defensible, who names Nektar Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
198 figures on this page: 187 cited to the filing that reported them, 11 calculated from figures it prints.
187 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001213900-26-065845
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001140361-26-016708
    DIRECTOR COMPENSATION TABLE—FISCAL 2025 · GRANTS OF PLAN BASED AWARDS IN 2025 · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END FOR 2025 · SUMMARY COMPENSATION TABLE—FISCAL 2023-2025
  3. 0001213900-25-047890
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001140361-25-015744
    Summary Compensation Table
  5. 0001213900-24-050365
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001140361-24-022440
    Summary Compensation Table
  7. 0001213900-23-047824
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001213900-22-032131
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001213900-21-032525
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001213900-20-015571
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001213900-19-010823
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001615774-18-005785
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001615774-17-003196
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001615774-16-006085
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Nektar Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/NKTR (accessed 2026).
Short form: data: Velarion

The paid brief for Nektar Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Nektar Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Nektar Therapeutics discloses

The companies named in NKTR's own disclosed peer group.

Amylyx PharmaceuticalsArcus BiosciencesAstria TherapeuticsCelldex TherapeuticsCompass TherapeuticsDianthus TherapeuticsIDEAYA BiosciencesIntellia TherapeuticsKodiak SciencesOlema PharmaceuticalsPraxis Precision MedicinesRelay TherapeuticsRezoluteVera TherapeuticsViridian Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy